Pieris Pharmaceuticals Stock Scheduled to Reverse Split on Tuesday, April 23rd (NASDAQ:PIRS)

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)’s stock is scheduled to reverse split before the market opens on Tuesday, April 23rd. The 1-80 reverse split was announced on Tuesday, April 23rd. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, April 23rd.

Pieris Pharmaceuticals Stock Performance

Shares of PIRS opened at $0.15 on Friday. The company has a market capitalization of $14.34 million, a price-to-earnings ratio of -0.52 and a beta of 0.48. The company’s 50 day simple moving average is $0.17 and its 200 day simple moving average is $0.20. Pieris Pharmaceuticals has a 1 year low of $0.14 and a 1 year high of $1.01.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Friday, March 29th. The biotechnology company reported ($0.05) earnings per share for the quarter. The company had revenue of $1.30 million for the quarter. Pieris Pharmaceuticals had a negative return on equity of 90.17% and a negative net margin of 57.33%.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Pieris Pharmaceuticals in a research note on Saturday, April 13th. They set a “hold” rating on the stock.

Hedge Funds Weigh In On Pieris Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its stake in shares of Pieris Pharmaceuticals by 9,665.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 21,581 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 21,360 shares during the period. Raymond James & Associates raised its stake in shares of Pieris Pharmaceuticals by 50.0% in the 4th quarter. Raymond James & Associates now owns 30,000 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 10,000 shares during the period. Oppenheimer & Co. Inc. purchased a new position in shares of Pieris Pharmaceuticals in the 1st quarter valued at $32,000. Mirabella Financial Services LLP purchased a new position in shares of Pieris Pharmaceuticals in the 1st quarter valued at $39,000. Finally, Two Sigma Investments LP purchased a new position in shares of Pieris Pharmaceuticals in the 3rd quarter valued at $43,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.